Omicron: The Lowdown
The COVID pandemic started at the turn of 2020. The virus was first detected in Wuhan, China and since then has spread around the globe and mutated into several different
?>
The COVID pandemic started at the turn of 2020. The virus was first detected in Wuhan, China and since then has spread around the globe and mutated into several different
Hvivo will enrol healthy volunteers to test the efficacy of a biotech company’s oral vaccine candidate for Covid-19. A subsidiary of Dublin-based pharma services company Open Orphan said it is
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary
The winter season can wreak havoc on your immune system, particularly when we spend much of our time huddled indoors, and our diet may become a little more carbohydrate based.
The flu jab has encountered some controversy during its time in circulation. However, recent research suggests that some of these rumoured negative effects may in fact not be true –
For 20+ years, members of the CMC (Chemistry, Manufacturing and Controls) team supported numerous (bio)pharmaceutical and biotechnological companies to ensure the development and manufacture of high-quality drug substances and drug
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a
Revenue at the pharmaceutical services company increased almost 80 per cent last year after it secured a number of large contracts Open Orphan, the Dublin-listed pharmaceutical services company led by
Open Orphan plc (LON:ORPH) Chief Executive Officer Yamin ‘Mo’ Khan talks through the FY2021 Financial Results and the outlook for 2022. Mo covers topics:The Vision,The Numbers,Overview,Key Strategic Value Adding Initiatives,Summary Financial
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment